PATIENT RESOURCES
NeuBase is currently in the preclinical drug development phase of delivering precision genetic medicines for myotonic dystrophy type 1 (DM1), Huntington's disease (HD), and cancers driven by KRAS G12D and G12V mutations. If you would like to stay informed of our progress, please sign up for updates.
Keep me updated